Literature DB >> 25554644

Macrophage depletion ameliorates nephritis induced by pathogenic antibodies.

Samantha A Chalmers1, Violeta Chitu2, Leal C Herlitz3, Ranjit Sahu4, E Richard Stanley2, Chaim Putterman5.   

Abstract

Kidney involvement affects 40-60% of patients with lupus, and is responsible for significant morbidity and mortality. Using depletion approaches, several studies have suggested that macrophages may play a key role in the pathogenesis of lupus nephritis. However, "off target" effects of macrophage depletion, such as altered hematopoiesis or enhanced autoantibody production, impeded the determination of a conclusive relationship. In this study, we investigated the role of macrophages in mice receiving rabbit anti-glomerular antibodies, or nephrotoxic serum (NTS), an experimental model which closely mimics the immune complex mediated disease seen in murine and human lupus nephritis. GW2580, a selective inhibitor of the colony stimulating factor-1 (CSF-1) receptor kinase, was used for macrophage depletion. We found that GW2580-treated, NTS challenged mice did not develop the increased levels of proteinuria, serum creatinine, and BUN seen in control-treated, NTS challenged mice. NTS challenged mice exhibited significantly increased kidney expression of inflammatory cytokines including RANTES, IP-10, VCAM-1 and iNOS, whereas GW2580-treated mice were protected from the robust expression of these inflammatory cytokines that are associated with lupus nephritis. Quantification of macrophage related gene expression, flow cytometry analysis of kidney single cell suspensions, and immunofluorescence staining confirmed the depletion of macrophages in GW2580-treated mice, specifically within renal glomeruli. Our results strongly implicate a specific and necessary role for macrophages in the development of immune glomerulonephritis mediated by pathogenic antibodies, and support the development of macrophage targeting approaches for the treatment of lupus nephritis.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Lupus nephritis; Macrophages; Nephrotoxic serum nephritis (NTS); SLE

Mesh:

Substances:

Year:  2014        PMID: 25554644      PMCID: PMC4323927          DOI: 10.1016/j.jaut.2014.11.007

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  48 in total

1.  Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis.

Authors:  Simon Yona; Ki-Wook Kim; Yochai Wolf; Alexander Mildner; Diana Varol; Michal Breker; Dalit Strauss-Ayali; Sergey Viukov; Martin Guilliams; Alexander Misharin; David A Hume; Harris Perlman; Bernard Malissen; Elazar Zelzer; Steffen Jung
Journal:  Immunity       Date:  2012-12-27       Impact factor: 31.745

2.  Reduced macrophage recruitment, proliferation, and activation in colony-stimulating factor-1-deficient mice results in decreased tubular apoptosis during renal inflammation.

Authors:  Deborah M Lenda; Eriya Kikawada; E Richard Stanley; Vicki R Kelley
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

Review 3.  Colony-stimulating factor-1 in immunity and inflammation.

Authors:  Violeta Chitu; E Richard Stanley
Journal:  Curr Opin Immunol       Date:  2005-12-06       Impact factor: 7.486

4.  The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation.

Authors:  Sayan Nandi; Solen Gokhan; Xu-Ming Dai; Suwen Wei; Grigori Enikolopov; Haishan Lin; Mark F Mehler; E Richard Stanley
Journal:  Dev Biol       Date:  2012-04-19       Impact factor: 3.582

Review 5.  Matrix metalloproteinase-9 and autoimmune diseases.

Authors:  Maya Ram; Yaniv Sherer; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

6.  Primed innate immunity leads to autoinflammatory disease in PSTPIP2-deficient cmo mice.

Authors:  Violeta Chitu; Polly J Ferguson; Rosalie de Bruijn; Annette J Schlueter; Luis A Ochoa; Thomas J Waldschmidt; Yee-Guide Yeung; E Richard Stanley
Journal:  Blood       Date:  2009-07-16       Impact factor: 22.113

7.  Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway.

Authors:  Jing Wen; Yumin Xia; Ariel Stock; Jennifer S Michaelson; Linda C Burkly; Maria Gulinello; Chaim Putterman
Journal:  J Autoimmun       Date:  2013-04-08       Impact factor: 7.094

8.  CSF-1 receptor-mediated differentiation of a new type of monocytic cell with B cell-stimulating activity: its selective dependence on IL-34.

Authors:  Fumihiro Yamane; Yumiko Nishikawa; Kazue Matsui; Miki Asakura; Eriko Iwasaki; Koji Watanabe; Hikaru Tanimoto; Hiroki Sano; Yuki Fujiwara; E Richard Stanley; Naoki Kanayama; Neil A Mabbott; Masaki Magari; Hitoshi Ohmori
Journal:  J Leukoc Biol       Date:  2013-09-19       Impact factor: 4.962

9.  HMGB1: a smoking gun in lupus nephritis?

Authors:  David S Pisetsky
Journal:  Arthritis Res Ther       Date:  2012-03-14       Impact factor: 5.156

10.  Distribution of cells bearing receptors for a colony-stimulating factor (CSF-1) in murine tissues.

Authors:  P V Byrne; L J Guilbert; E R Stanley
Journal:  J Cell Biol       Date:  1981-12       Impact factor: 10.539

View more
  37 in total

1.  Critical Role of Macrophage FcγR Signaling and Reactive Oxygen Species in Alloantibody-Mediated Hepatocyte Rejection.

Authors:  Jason M Zimmerer; Xin L Liu; Alecia Blaszczak; Christina L Avila; Thomas A Pham; Robert T Warren; Ginny L Bumgardner
Journal:  J Immunol       Date:  2018-11-05       Impact factor: 5.422

2.  Fn14 deficiency protects lupus-prone mice from histological lupus erythematosus-like skin inflammation induced by ultraviolet light.

Authors:  Jessica Doerner; Samantha A Chalmers; Adam Friedman; Chaim Putterman
Journal:  Exp Dermatol       Date:  2016-12       Impact factor: 3.960

Review 3.  Neuropsychiatric lupus: new mechanistic insights and future treatment directions.

Authors:  Noa Schwartz; Ariel D Stock; Chaim Putterman
Journal:  Nat Rev Rheumatol       Date:  2019-03       Impact factor: 20.543

Review 4.  Biomarkers for kidney involvement in pediatric lupus.

Authors:  Beatrice Goilav; Chaim Putterman; Tamar B Rubinstein
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

5.  Deficiency in IRAK4 activity attenuates manifestations of murine Lupus.

Authors:  Michael Murphy; Goutham Pattabiraman; Tissa T Manavalan; Andrei E Medvedev
Journal:  Eur J Immunol       Date:  2017-03-31       Impact factor: 5.532

6.  NF-kB signaling in myeloid cells mediates the pathogenesis of immune-mediated nephritis.

Authors:  Samantha A Chalmers; Sayra J Garcia; Joshua A Reynolds; Leal Herlitz; Chaim Putterman
Journal:  J Autoimmun       Date:  2019-01-03       Impact factor: 7.094

7.  Lipocalin-2 is a pathogenic determinant and biomarker of neuropsychiatric lupus.

Authors:  Elise V Mike; Hadijat M Makinde; Maria Gulinello; Kamala Vanarsa; Leal Herlitz; Gaurav Gadhvi; Deborah R Winter; Chandra Mohan; John G Hanly; C C Mok; Carla M Cuda; Chaim Putterman
Journal:  J Autoimmun       Date:  2018-08-30       Impact factor: 7.094

8.  TNF-α in T lymphocytes attenuates renal injury and fibrosis during nephrotoxic nephritis.

Authors:  Yi Wen; Nathan P Rudemiller; Jiandong Zhang; Taylor Robinette; Xiaohan Lu; Jiafa Ren; Jamie R Privratsky; Sergei A Nedospasov; Steven D Crowley
Journal:  Am J Physiol Renal Physiol       Date:  2019-11-18

Review 9.  Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases.

Authors:  John A Hamilton; Andrew D Cook; Paul P Tak
Journal:  Nat Rev Drug Discov       Date:  2016-12-29       Impact factor: 84.694

10.  CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus.

Authors:  Samantha A Chalmers; Jing Wen; Justine Shum; Jessica Doerner; Leal Herlitz; Chaim Putterman
Journal:  Clin Immunol       Date:  2016-08-26       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.